Research progress of CCR8 in tumor immunotherapy

Yifan CHEN; Ting LI; Biyun WANG

doi:10.19401/j.cnki.1007-3639.2024.03.008

您当前的位置：

首页 >

文章列表页 >

Research progress of CCR8 in tumor immunotherapy

Review | 更新时间：2025-12-31

- Research progress of CCR8 in tumor immunotherapy
- China Oncology Vol. 34, Issue 3, Pages: 299-305(2024)
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺及泌尿肿瘤内科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.03.008
  CLC： R730.51
- Received：01 August 2023，
  
  Revised：2023-11-28，
  
  Published：30 March 2024
- 稿件说明：
移动端阅览
Yifan CHEN, Ting LI, Biyun WANG. Research progress of CCR8 in tumor immunotherapy[J]. China Oncology, 2024, 34(3): 299-305.
DOI：

Yifan CHEN, Ting LI, Biyun WANG. Research progress of CCR8 in tumor immunotherapy[J]. China Oncology, 2024, 34(3): 299-305. DOI： 10.19401/j.cnki.1007-3639.2024.03.008.

摘要

目前针对肿瘤的治疗方法不断进步，免疫治疗已成为遏制肿瘤进展的有效手段。但目前的免疫治疗仍有局限性，只有较少的一部分特定患者可以从免疫治疗中完全获益。由于复杂的肿瘤微环境取决于不同的个体，所以免疫靶向药物在不同的肿瘤微环境中会受到不同程度的免疫抑制，从而无法发挥全部作用。在肿瘤微环境中，调节性T（regulatory T，Treg）细胞起到免疫抑制的作用，在许多瘤种中Treg细胞大量浸润从而造成肿瘤组织的免疫逃逸，会对治疗和预后产生不良影响。CC族趋化因子受体8（CC chemokine receptor 8，CCR8）属于CC族趋化因子受体家族，其主要在肿瘤微环境中的Treg细胞上特异性高表达，而在周围正常组织和外周血中低表达，因此CCR8可以作为Treg细胞的一种特异性标志物，是一种有潜力的治疗靶点和生物标志物。本文对近年来CCR8在不同瘤种中的研究进展进行了归纳和总结，以期为后续研究提供参考。

Abstract

Therapies for tumors continue to develop

and tumor immunotherapy has emerged as an effective means of controlling tumor progression. Given the limitations of immunotherapy

only some specific patients can benefit from immunotherapy. Since the complex tumor microenvironment is highly influenced by individual variability

immunotherapy will be subjected to different degrees of immune suppression in different tumor microenvironments and thus cannot exert its full effect. In the tumor microenvironment

regulatory T (Treg) cell plays as an immunosuppressive role. Numerous Treg cells infiltrate in indifferent tumor types

resulting in immune escape of tumor tissues

which will have a negative impact on treatment and prognosis. CC chemokine receptor 8 (CCR8) belongs to the CC chemokine receptor family. CCR8 is specifically expressed on Treg cell in the tumor microenvironment and expressed at low level in the surrounding normal tissues and peripheral blood thus it can be a specific marker for Treg cell. CCR8 is a potential therapeutic target and biomarker. This review summarized the research progress of CCR8 in different tumor types in recent years

so as to provide reference for subsequent research.

关键词

Keywords

references

WEAVER J D , STACK E C , BUGGÉ J A , et al . Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody [J ] . Oncoimmunology , 2022 , 11 ( 1 ): 2141007.

VAN DAMME H , DOMBRECHT B , KISS M , et al . Therapeutic depletion of CCR8 + tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy [J ] . J Immunother Cancer , 2021 , 9 ( 2 ): e001749.

MOSER B . Chemokine receptor-targeted therapies: special case for CCR8 [J ] . Cancers , 2022 , 14 ( 3 ): 511.

MCCULLY M L , MOSER B . The human cutaneous chemokine system [J ] . Front Immunol , 2011 , 2 : 33 . DOI: 10.3389/fimmu.2011.00033 http://doi.org/10.3389/fimmu.2011.00033

KARIN N . Chemokines and cancer: new immune checkpoints for cancer therapy [J ] . Curr Opin Immunol , 2018 , 51 : 140 - 145 . DOI: S0952-7915(17)30141-3 http://doi.org/S0952-7915(17)30141-3

KUEHNEMUTH B , PISEDDU I , WIEDEMANN G M , et al . CCL1 is a major regulatory T cell attracting factor in human breast cancer [J ] . BMC Cancer , 2018 , 18 ( 1 ): 1278.

LIU S S , LIU C , LV X X , et al . The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis [J ] . Immunity , 2021 , 54 ( 10 ): 2433 - 2435 . DOI: 10.1016/j.immuni.2021.09.009 http://doi.org/10.1016/j.immuni.2021.09.009 https://linkinghub.elsevier.com/retrieve/pii/S1074761321003940 https://linkinghub.elsevier.com/retrieve/pii/S1074761321003940

CHEN B W , ZHANG S Y , LI Q Y , et al . Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment [J ] . Biosci Rep , 2020 , 40 ( 11 ): BSR2 0202042.

LOU X L , ZHAO K , XU J Z , et al . CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: a bioinformatic analysis of the tumor microenvironment [J ] . Front Immunol , 2022 , 13 : 950213 . DOI: 10.3389/fimmu.2022.950213 http://doi.org/10.3389/fimmu.2022.950213 https://www.frontiersin.org/articles/10.3389/fimmu.2022.950213/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.950213/full

CHENIVESSE C , TSICOPOULOS A . CCL18 - beyond chemotaxis [J ] . Cytokine , 2018 , 109 : 52 - 56 . DOI: S1043-4666(18)30034-6 http://doi.org/S1043-4666(18)30034-6

KORBECKI J , KOJDER K , SIMIŃSKA D , et al . CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4 [J ] . Int J Mol Sci , 2020 , 21 ( 21 ): 8412.

PLITAS G , RUDENSKY A Y . Regulatory T cells in cancer [J ] . Annu Rev Cancer Biol , 2020 , 4 : 459 - 477 . DOI: 10.1146/cancerbio.2020.4.issue-1 http://doi.org/10.1146/cancerbio.2020.4.issue-1 https://www.annualreviews.org/toc/cancerbio/4/1 https://www.annualreviews.org/toc/cancerbio/4/1

WING J B , TANAKA A , SAKAGUCHI S . Human FOXP3 + regulatory T cell heterogeneity and function in autoimmunity and cancer [J ] . Immunity , 2019 , 50 ( 2 ): 302 - 316 . DOI: 10.1016/j.immuni.2019.01.020 http://doi.org/10.1016/j.immuni.2019.01.020 https://linkinghub.elsevier.com/retrieve/pii/S1074761319300433 https://linkinghub.elsevier.com/retrieve/pii/S1074761319300433

ANGELOVA M , CHAROENTONG P , HACKL H , et al . Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy [J ] . Genome Biol , 2015 , 16 ( 1 ): 64.

DE SIMONE M , ARRIGONI A , ROSSETTI G , et al . Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells [J ] . Immunity , 2016 , 45 ( 5 ): 1135 - 1147 . DOI: S1074-7613(16)30432-0 http://doi.org/S1074-7613(16)30432-0

SUN F , ZHANG C , AI S C , et al . Identification of hub genes in gastric cancer by integrated bioinformatics analysis [J ] . Transl Cancer Res , 2021 , 10 ( 6 ): 2831 - 2840 . DOI: 10.21037/tcr-20-3540 http://doi.org/10.21037/tcr-20-3540

WEI F Z , MEI S W , WANG Z J , et al . HAMP as a prognostic biomarker for colorectal cancer based on tumor microenvironment analysis [J ] . Front Oncol , 2022 , 12 : 884474 . DOI: 10.3389/fonc.2022.884474 http://doi.org/10.3389/fonc.2022.884474 https://www.frontiersin.org/articles/10.3389/fonc.2022.884474/full https://www.frontiersin.org/articles/10.3389/fonc.2022.884474/full

VILLARREAL D O , L’HUILLIER A , ARMINGTON S , et al . Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer [J ] . Cancer Res , 2018 , 78 ( 18 ): 5340 - 5348 . DOI: 10.1158/0008-5472.CAN-18-1119 http://doi.org/10.1158/0008-5472.CAN-18-1119

PLITAS G , KONOPACKI C , WU K M , et al . Regulatory T cells exhibit distinct features in human breast cancer [J ] . Immunity , 2016 , 45 ( 5 ): 1122 - 1134 . DOI: S1074-7613(16)30443-5 http://doi.org/S1074-7613(16)30443-5

WANG L , SIMONS D L , LU X Y , et al . Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer [J ] . Nat Immunol , 2019 , 20 ( 9 ): 1220 - 1230 . DOI: 10.1038/s41590-019-0429-7 http://doi.org/10.1038/s41590-019-0429-7

RUCKES T , SAUL D , VAN SNICK J , et al . Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309 [J ] . Blood , 2001 , 98 ( 4 ): 1150 - 1159 . DOI: 10.1182/blood.v98.4.1150 http://doi.org/10.1182/blood.v98.4.1150

RONSLEY R , KARIMINIA A , NG B , et al . The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: results of the TACL T2009-008 phase I study [J ] . Pediatr Hematol Oncol , 2019 , 36 ( 8 ): 468 - 481 . DOI: 10.1080/08880018.2019.1667461 http://doi.org/10.1080/08880018.2019.1667461

ZHENG D W , WANG X D , CHENG L , et al . The chemokine receptor CCR8 is a target of chimeric antigen T cells for treating T cell malignancies [J ] . Front Immunol , 2022 , 13 : 808347 . DOI: 10.3389/fimmu.2022.808347 http://doi.org/10.3389/fimmu.2022.808347 https://www.frontiersin.org/articles/10.3389/fimmu.2022.808347/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.808347/full

ERUSLANOV E , STOFFS T , KIM W J , et al . Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas [J ] . Clin Cancer Res , 2013 , 19 ( 7 ): 1670 - 1680 . DOI: 10.1158/1078-0432.CCR-12-2091 http://doi.org/10.1158/1078-0432.CCR-12-2091

LIU X Q , XU X Y , DENG W , et al . CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells [J ] . Mol Med Rep , 2019 , 19 ( 3 ): 1678 - 1686 . DOI: 10.3892/mmr.2018.9791 http://doi.org/10.3892/mmr.2018.9791

WANG T , ZHOU Q , ZENG H , et al . CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer [J ] . Cancer Immunol Immunother , 2020 , 69 ( 9 ): 1855 - 1867 . DOI: 10.1007/s00262-020-02583-y http://doi.org/10.1007/s00262-020-02583-y

SUN Y X , ZHANG Q , YAO L L , et al . Comprehensive analysis reveals novel gene signature in head and neck squamous cell carcinoma: predicting is associated with poor prognosis in patients [J ] . Transl Cancer Res , 2020 , 9 ( 10 ): 5882 - 5892 . DOI: 10.21037/tcr-20-805 http://doi.org/10.21037/tcr-20-805

MENG L L , HE X X , HONG Q , et al . CCR4, CCR8, and P2RY14 as prognostic factors in head and neck squamous cell carcinoma are involved in the remodeling of the tumor microenvironment [J ] . Front Oncol , 2021 , 11 : 618187 . DOI: 10.3389/fonc.2021.618187 http://doi.org/10.3389/fonc.2021.618187 https://www.frontiersin.org/articles/10.3389/fonc.2021.618187/full https://www.frontiersin.org/articles/10.3389/fonc.2021.618187/full

FRAGA M , YÁÑEZ M , SHERMAN M , et al . Immunomodulation of T helper cells by tumor microenvironment in oral cancer is associated with CCR8 expression and rapid membrane vitamin D signaling pathway [J ] . Front Immunol , 2021 , 12 : 643298 . DOI: 10.3389/fimmu.2021.643298 http://doi.org/10.3389/fimmu.2021.643298 https://www.frontiersin.org/articles/10.3389/fimmu.2021.643298/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.643298/full

FUJIKAWA M , KOMA Y I , HOSONO M , et al . Chemokine (C-C motif) ligand 1 derived from tumor-associated macrophages contributes to esophageal squamous cell carcinoma progression via CCR8-mediated Akt/proline-rich Akt substrate of 40 kDa/mammalian target of rapamycin pathway [J ] . Am J Pathol , 2021 , 191 ( 4 ): 686 - 703 . DOI: 10.1016/j.ajpath.2021.01.004 http://doi.org/10.1016/j.ajpath.2021.01.004

HARUNA M , UEYAMA A , YAMAMOTO Y , et al . The impact of CCR8 + regulatory T cells on cytotoxic T cell function in human lung cancer [J ] . Sci Rep , 2022 , 12 ( 1 ): 5377.

DAS S , SARROU E , PODGRABINSKA S , et al . Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses [J ] . J Exp Med , 2013 , 210 ( 8 ): 1509 - 1528 . DOI: 10.1084/jem.20111627 http://doi.org/10.1084/jem.20111627 https://rupress.org/jem/article/210/8/1509/41426/Tumor-cell-entry-into-the-lymph-node-is-controlled https://rupress.org/jem/article/210/8/1509/41426/Tumor-cell-entry-into-the-lymph-node-is-controlled

BERENGUER J , LAGERWEIJ T , ZHAO X W , et al . Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8 [J ] . J Extracell Vesicles , 2018 , 7 ( 1 ): 1446660.

HUANG Y M , MOTTA E , NANVUMA C , et al . Microglia/macrophage-derived human CCL18 promotes glioma progression via CCR8-ACP5 axis analyzed in humanized slice model [J ] . Cell Rep , 2022 , 39 ( 2 ): 110670.

GIUSTINIANI J , DOBOS G , MOINS-TEISSERENC H , et al . CCR8 is a new therapeutic target in cutaneous T-cell lymphomas [J ] . Blood Adv , 2022 , 6 ( 11 ): 3507 - 3512 . DOI: 10.1182/bloodadvances.2021006512 http://doi.org/10.1182/bloodadvances.2021006512

CAMPBELL J R , MCDONALD B R , MESKO P B , et al . Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models [J ] . Cancer Res , 2021 , 81 ( 11 ): 2983 - 2994 . DOI: 10.1158/0008-5472.CAN-20-3585 http://doi.org/10.1158/0008-5472.CAN-20-3585 https://aacrjournals.org/cancerres/article/81/11/2983/673682/Fc-Optimized-Anti-CCR8-Antibody-Depletes https://aacrjournals.org/cancerres/article/81/11/2983/673682/Fc-Optimized-Anti-CCR8-Antibody-Depletes

KIDANI Y , NOGAMI W , YASUMIZU Y , et al . CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory [J ] . Proc Natl Acad Sci U S A , 2022 , 119 ( 7 ): e211 4282119.

WHITESIDE S K , GRANT F M , GYORI D S , et al . CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function [J ] . Immunology , 2021 , 163 ( 4 ): 512 - 520 . DOI: 10.1111/imm.13337 http://doi.org/10.1111/imm.13337

LIU F T , WU H Y . CC chemokine receptors in lung adenocarcinoma: the inflammation-related prognostic biomarkers and immunotherapeutic targets [J ] . J Inflamm Res , 2021 , 14 : 267 - 285 . DOI: 10.2147/JIR.S278395 http://doi.org/10.2147/JIR.S278395

LI H L , WANG L H , HU Y L , et al . Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors [J ] . World J Gastroenterol , 2020 , 26 ( 31 ): 4656 - 4668 . DOI: 10.3748/wjg.v26.i31.4656 http://doi.org/10.3748/wjg.v26.i31.4656 https://www.wjgnet.com/1007-9327/full/v26/i31/4656.htm https://www.wjgnet.com/1007-9327/full/v26/i31/4656.htm

CHEN G , CAI Z D , LIN Z Y , et al . ARNT-dependent CCR8 reprogrammed LDH isoform expression correlates with poor clinical outcomes of prostate cancer [J ] . Mol Carcinog , 2020 , 59 ( 8 ): 897 - 907 . DOI: 10.1002/mc.v59.8 http://doi.org/10.1002/mc.v59.8 https://onlinelibrary.wiley.com/toc/10982744/59/8 https://onlinelibrary.wiley.com/toc/10982744/59/8

YI G , GUO S W , LIU W Y , et al . Identification and functional analysis of heterogeneous FOXP3 + Treg cell subpopulations in human pancreatic ductal adenocarcinoma [J ] . Sci Bull , 2018 , 63 ( 15 ): 972 - 981 . DOI: 10.1016/j.scib.2018.05.028 http://doi.org/10.1016/j.scib.2018.05.028 https://linkinghub.elsevier.com/retrieve/pii/S2095927318302500 https://linkinghub.elsevier.com/retrieve/pii/S2095927318302500

Views

2303

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Research status and progress of third-line treatment for metastatic colorectal cancer

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Research status and prospects of treatment for malignant pleural mesothelioma

Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer

Related Author

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

ZHANG Ruixing

Jingyu LIU

Tong YIN

Related Institution

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Oncology, The First Affiliated Hospital of Naval Medical University

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

AI问答

⁰